References
- Faaij RA, Srivastava N, Van Griensven JMT, Schoemaker RC, Kluft C, Burggraaf J, Cohen AF. The oral bioavailability of pentosan polysulfate sodium in healthy volunteers. European Journal of Clinical Pharmacology 1999; 54: 929–935
- Fellström B, Björklund U, Danielson BG, Eriksson H, Odlind B, Tengblad A. Pentosan polysulfate (ELMIRON®): Pharmacokinetics and effects on the urinary inhibition of crystal growth. Pathogenese und klinik der harnsteine, W Vahlensieck, G Gassner. Steinkopff, Darmstadt 1987; 340–396, editors.
- Kirkman SK, Hultin TA, Scatina J. Distribution and excretion of 125I-ardeparin, a low molecular weight heparin, in rats and beagle dogs. Drug Metabolism and Disposition 1994; 22: 175–176
- MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M. Metabolism of sodium pentosan polysulfate in man — catabolism of iodinated derivatives. Thrombosis and Haemostasis 1984; 51: 321–325
- Marshall JL, Wellstein A, Rae J, DeLap RJ, Phipps K, Hanfelt J, Yunmbam MK, Sun JX, Duchin KL, Hawkins MJ. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clinical Cancer Research 1997; 3: 2347–2354
- Odlind B, Dencker L, Tengblad A. Preferential localization of 3H-pentosanpolysulfate to the urinary tract in rats. Pharmacology and Toxicology 1987; 61: 162–166